We experienced a case of giant localized fibrous pleural mesothelioma accompanying lung metastasis. The patient was a 26-year-old woman, who was pointed out elevation of the left diaphragma by the chest roentgenogram in 1992 but left it as it was. In 1995, a giant tumor occupying 1/2 or more of the left thoracic cavity was detected by chest CT and MRI. A giant localized pleural mesothelioma was suspected since there was no accumulation in Ga scintigram and an operation was performed. The tumor originated without pedicle and with invasion of the lung from the pleura of the left S8 and it was excised by separating the left lower lobe at 7-cm distance from the tumor. The tumor was 20 x 12 x 11 cm in size weighing 1700 g and the histopathological diagnosis was localized fibrous pleural mesothelioma. A lung metastasis of 1.0 cm in size was found in a part of the left lower lobe resected at the same time. The postoperative course has been satisfactory and there is no sign of recurrence at present. There are occasional cases of recurrence associated with a localized fibrous pleural mesothelioma even though it is judged benign. In the present case, a metastatic focus was already present at the time of initial surgery and is considered a valuable case.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pleural mesothelioma
20
localized fibrous
16
fibrous pleural
16
mesothelioma accompanying
8
accompanying lung
8
giant localized
8
lung metastasis
8
left lower
8
lower lobe
8
left
6

Similar Publications

Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with a poor prognosis. Identifying reliable prognostic factors is crucial for risk stratification and optimizing treatment strategies. This study aimed to evaluate the impact of clinicopathologic factors and systemic inflammatory markers on survival outcomes in patients with MPM.

View Article and Find Full Text PDF

Background/objectives: Telomerase reverse transcriptase (TERT) is the catalytic subunit of the telomerase enzyme responsible for telomere length maintenance and is an important cancer hallmark. Our study aimed to clarify the mRNA expression of TERT in peritoneal mesothelioma (PeM), and to explore the relationship between its expression and the clinicopathological parameters and prognosis of patients with PeM.

Methods: In a cohort of 13 MpeM patients, we evaluated histotype, nuclear grade, mitotic count, necrosis, inflammation, Ki67, BAP1, MTAP and p16 expression by immunohistochemistry, / status by FISH and TERT mRNA expression by RNAscope.

View Article and Find Full Text PDF

Cytoreductive surgery in diffuse pleural mesothelioma. What have we learnt from MARS2, EORTC-L1205 and other recent studies?

Eur J Surg Oncol

January 2025

Department of Surgery, Clinique de Genolier, Genolier, Switzerland. Electronic address:

Cytoreductive surgery remains controversial in pleural mesothelioma. The MARS2 trial suggested that extended pleurectomy decortication following neoadjuvant chemotherapy was associated with no survival benefit, more serious adverse events and poorer quality of life than systemic chemotherapy alone in patients with resectable pleural mesothelioma. However, patient selection, chemotherapy scheme, high surgical mortality (9 %) and poor outcomes in the surgical cohort have been raised by mesothelioma experts as potential issues in MARS2.

View Article and Find Full Text PDF

Malignant pleural mesothelioma (MPM) is a rare neoplasm with increasing incidence and mortality rates. Although recent advances have improved the overall prognosis, they have not had an important impact on survival of patients with MPM, such that more effective treatments are needed. Some species of marine snails have been demonstrated to be potential sources of novel anticancer molecules.

View Article and Find Full Text PDF

Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity, and clinical activity of adjuvant vaccination with Wilms' tumor protein (WT1) mRNA-electroporated autologous dendritic cells (WT1-mRNA/DC) in a single-arm phase I/II clinical study of patients with advanced solid tumors receiving standard therapy. Disease status and immune reactivity were evaluated after 8 weeks and 6 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!